Novartis: positive Phase III data for asciminib
(CercleFinance.com) - Novartis has announced that in the first analysis, its Phase III study ASCEMBL has reached its primary endpoint of statistically significant superiority in the major molecular response rate at 24 weeks for asciminib (ABL001) compared to bosutinib.
For the record, the study evaluates the investigational treatment asciminib in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with at least two tyrosine kinase inhibitors.
Data from this trial will be presented at an upcoming medical congress and its results will be shared with regulatory authorities. FDA in the US has granted fast-track designation for asciminib.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
For the record, the study evaluates the investigational treatment asciminib in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with at least two tyrosine kinase inhibitors.
Data from this trial will be presented at an upcoming medical congress and its results will be shared with regulatory authorities. FDA in the US has granted fast-track designation for asciminib.
Copyright (c) 2020 CercleFinance.com. All rights reserved.